Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Status Completed

Clinical Trial Summary

This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2% over vehicle, in subjects with mild to moderate AD. Two identified AD skin lesions for each subject will be treated for the first 15 days, one with crisaborole ointment 2% and one with vehicle, in a blinded manner, and biopsies for biomarker analysis will be performed on the lesions. Following completion of the blinded treatment period, subjects will start the 28 day open label period during which all AD affected skin lesions will be treated with crisaborole ointment 2% twice daily.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03233529
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	July 31, 2017
Completion date	May 4, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Terminated	`NCT04086121` - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032	Phase 2
Recruiting	`NCT04011215` - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)	N/A
Completed	`NCT04635072` - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis	Early Phase 1
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT01945086` - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis	Phase 2
Completed	`NCT00541255` - A Long-Term Examination of Asthma From Childhood Through Adolescence
Terminated	`NCT04990440` - A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis	Phase 2
Completed	`NCT02900131` - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients	Phase 2
Completed	`NCT03568136` - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis	Phase 2
Recruiting	`NCT01631617` - Effects of Treatments on Atopic Dermatitis	Phase 2
Completed	`NCT03672383` - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)	N/A
Completed	`NCT03634345` - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.	Phase 1
Enrolling by invitation	`NCT04761978` - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed	`NCT03663673` - Effect of Different Skin Creams on TEWL	Phase 1
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Completed	`NCT02637206` - Skin Irritation Study of GSK2894512 Cream	Phase 1
Completed	`NCT05544591` - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT05094700` - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants	N/A